This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Date:

November 13, 2024

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for major depressive disorder, or MDD, later this year.

Source link

Phillip Lim Steps Down as Creative Director of 3.1 Phillip Lim

Nelly Furtado Says She Endured ‘Abusive Qualities' in Past Relationship

Alexandra Williams

Alexandra Williams is a writer and editor. Angeles. She writes about politics, art, and culture for LinkDaddy News.

This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Recent posts

Fed’s Barkin: More data is needed before any changes are made to interest rates

This popular ‘Trump trade’ may have run its course — at least for now, strategist says

Eli Lilly’s stock soars as Mounjaro, Zepbound sales lead to a big profit beat

Boeing’s confidence in Starliner ‘speaks volumes,’ says former NASA astronaut

Tesla reports this week. The focus could shift ‘back to fundamentals’.

Newell’s stock soars after earnings again, as turnaround efforts take shape

Macy’s plans first-ever ‘All-Star Week’ for loyalty members as it squares up against rivals

Kamala Harris pitches student-loan forgiveness to teachers union: ‘A future where no teacher has to struggle with the burden’

Humana’s stock rocked after a Medicare Advantage plan’s rating is set to drop

How Tesla stock became a ‘Trump trade’ despite GOP climate skepticism

CarGurus shares rally after fourth-quarter forecast, but this hurdle lies ahead

Want to make more than $150,000? Job hopping may be your best bet — but it’s harder than it used to be.

Tesla’s market cap hits $1 trillion after another Trump-fueled jump for the stock

ASML says chip-market slump will mainly impact sales to China

Five Below’s stock tumbles on CEO departure and downbeat forecast

Related articles

Republicans clinch control of House, setting stage for quicker action on extending tax cuts

Cava is riding a strong wave, but the stock’s quadrupling in 2024 has analysts wary

Wells Fargo touches all-time high as analyst hikes price target to new level

Tesla is likely to thrive in a Trump administration. These are the ways these analysts see it happening.

Dogecoin soars as altcoins look to benefit from Trump presidency

GameStop’s stock continues its rise, registering longest winning streak in four months

Bitcoin is trading at record high near $85,000. Is it a good time to buy?

Fate of postelection stock-market rally may be in the hands of bond traders

Company

Follow us